MX2009007572A - Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y. - Google Patents

Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.

Info

Publication number
MX2009007572A
MX2009007572A MX2009007572A MX2009007572A MX2009007572A MX 2009007572 A MX2009007572 A MX 2009007572A MX 2009007572 A MX2009007572 A MX 2009007572A MX 2009007572 A MX2009007572 A MX 2009007572A MX 2009007572 A MX2009007572 A MX 2009007572A
Authority
MX
Mexico
Prior art keywords
fusion protein
antigen
proteins
fusion proteins
fusion
Prior art date
Application number
MX2009007572A
Other languages
English (en)
Spanish (es)
Inventor
Vincent Brichard
Clement Rioux
Martine Boyer
Denis Martin
Jamila Louahed
Normand Blais
Remi M Palmantier
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0709707A external-priority patent/GB0709707D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2009007572A publication Critical patent/MX2009007572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2009007572A 2007-01-15 2008-01-11 Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y. MX2009007572A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
US91492507P 2007-04-30 2007-04-30
US91484807P 2007-04-30 2007-04-30
GB0709707A GB0709707D0 (en) 2007-05-21 2007-05-21 Novel fusion protein
PCT/US2008/050879 WO2008089074A2 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1

Publications (1)

Publication Number Publication Date
MX2009007572A true MX2009007572A (es) 2009-10-13

Family

ID=41111108

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007572A MX2009007572A (es) 2007-01-15 2008-01-11 Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.

Country Status (15)

Country Link
EP (1) EP2118128B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010532656A (cg-RX-API-DMAC7.html)
KR (1) KR20090122426A (cg-RX-API-DMAC7.html)
BR (1) BRPI0806501A2 (cg-RX-API-DMAC7.html)
CA (1) CA2674458A1 (cg-RX-API-DMAC7.html)
DK (1) DK2118128T3 (cg-RX-API-DMAC7.html)
EA (1) EA016818B1 (cg-RX-API-DMAC7.html)
ES (1) ES2398492T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130022T1 (cg-RX-API-DMAC7.html)
MX (1) MX2009007572A (cg-RX-API-DMAC7.html)
PE (1) PE20081687A1 (cg-RX-API-DMAC7.html)
PL (1) PL2118128T3 (cg-RX-API-DMAC7.html)
SI (1) SI2118128T1 (cg-RX-API-DMAC7.html)
TW (1) TW200902049A (cg-RX-API-DMAC7.html)
WO (1) WO2008089074A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
CA2755734A1 (en) * 2009-03-17 2010-09-23 Gaetan Otto Improved detection of gene expression
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
AU2012302778B2 (en) * 2011-08-31 2016-11-24 Mie University Vaccine preparation for cancer treatment
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
EP3604271A1 (en) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptides for amino acid and peptide conjugates and conjugation process
JP6558699B2 (ja) 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
WO2017145097A2 (en) 2016-02-26 2017-08-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
AU2019383548A1 (en) * 2018-11-23 2021-06-24 Strike Pharma Ab Bi-specific conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
EP1272633B1 (en) * 2000-03-30 2011-04-27 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
EP1708741B1 (en) * 2003-12-24 2016-03-30 Aduro Biotech Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
BRPI0518933A2 (pt) * 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
WO2007137986A2 (en) * 2006-05-26 2007-12-06 Glaxosmithkline Biologicals Sa Vaccination against cancer
EP2114993B1 (en) * 2007-01-15 2012-08-29 GlaxoSmithKline Biologicals SA Vaccine

Also Published As

Publication number Publication date
BRPI0806501A2 (pt) 2014-04-22
PL2118128T3 (pl) 2013-03-29
PE20081687A1 (es) 2008-12-25
TW200902049A (en) 2009-01-16
EP2118128B1 (en) 2012-11-07
ES2398492T3 (es) 2013-03-19
EA200900738A1 (ru) 2010-02-26
DK2118128T3 (da) 2013-02-18
WO2008089074A2 (en) 2008-07-24
EP2118128A2 (en) 2009-11-18
CA2674458A1 (en) 2008-07-24
EA016818B1 (ru) 2012-07-30
WO2008089074A3 (en) 2008-12-31
SI2118128T1 (sl) 2013-02-28
WO2008089074A9 (en) 2012-07-12
HRP20130022T1 (hr) 2013-02-28
KR20090122426A (ko) 2009-11-30
JP2010532656A (ja) 2010-10-14

Similar Documents

Publication Publication Date Title
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
EP4364754A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2007039192A3 (en) Compositions and methods for treating tumors presenting survivin antigens
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
WO2006082406A3 (en) Human antibodies and proteins
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
WO2007067681A3 (en) Immunostimulatory compositions and methods
WO2009130618A3 (en) Flagellin polypeptide vaccines
TNSN07069A1 (en) Process for concentration of antibodies and therapeutic products thereof
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
WO2009133378A3 (en) Products and methods for stimulating an immune response
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
WO2014136064A3 (en) Immunogenic fusion polypeptides
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2012047267A3 (en) Polyvalent immunogen
EP4374913A3 (en) Novel human serum albumin mutant
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
WO2020074908A3 (en) Treatment and prevention of malaria based on the antigen pfrh5 and antibodies against the same
PT1951300E (pt) Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
UA97092C2 (ru) T-клеточные эпитопы с раково-эмбрионального антиген-незрелого рецепторного белка ламинина и их медицинское применение
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration